• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
Aildenafil Citrate Tablets
Retatrutide 2381089-83-2
98% Bifida Ferment Lysate
rhSOD (cosmetic grade)
Recombinant humanized collagen
Recombinant Humanized Small-molecule Collagen

FDA grants fast-track designation for Karyopharm's selinexor in penta-refractory multiple myeloma

firstwordpharmaApril 11, 2018

Tag: FDA , Karyopharm's selinexor

Karyopharm Therapeutics announced Tuesday that the FDA granted fast-track status to selinexor, the company's oral selective inhibitor of nuclear export (SINE) for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy. According to Karyopharm, the FDA's statement, which is consistent with the design of the company's Phase IIb STORM study, noted that the three prior lines of therapy include regimens comprised of an alkylating agent, a glucocorticoid, Velcade (bortezomib), Kyprolis (carfilzomib), Revlimid (lenalidomide), Pomalyst (pomalidomide) and Darzalex (daratumumab). 

Register as Visitor to CPhI China 2018!

Previous:CROMSOURCE Offers Clients One Trial One Price™ Guarantee

Next:Oliver Healthcare Packaging Expands Global Manufacturing Footprint to Strengthen Local Customer Support and Service in Asia Market

Related News

Xinhua Silk Road: Evaluation report highlights Seoul 120 hotline for its efficient operation

PRNewswireDecember 18, 2024

Seoul 120 hotline has contributed to efficient city operation, according to the Evaluation Report on Worldwide City Hotline Services and Governance Effectiveness (2024) released on Wednesday.

Gan & Lee Pharmaceuticals Announces U.S. FDA Clearance of the IND application for the innovative Bi-weekly GLP-1RA GZR18 Injection, Bofanglutide, with chronic weight management Indication (A Phase 2 h

PRNewswireDecember 18, 2024

Ascletis Announces ASC47, a Muscle-Preserving Weight Loss Drug Candidate for Treatment of Obesity, in Combination with Semaglutide, Demonstrated Superior Weight Loss to Semaglutide Monotherapy in a Pr

PRNewswireDecember 18, 2024

FDA grants fast-track designation for Karyopharm's selinexor in penta-refractory multiple myeloma | Pharmasources.com

Pharus Diagnostics LLC Announces Validation of a Laboratory-Developed Test for Early Pancreatic Cancer Detection

PRNewswireDecember 19, 2024

Pharus Diagnostics LLC. (PharusDx), announced a significant step forward in the fight against pancreatic cancer. The company is announcing availability of its OncoSweep™ Pancreas Spotlight

You may like
More>>

Sirolimus (FDA)

Sirolimus (FDA)
Fluorfenicol( FDA)

Fluorfenicol( FDA)
filter integrity testing fda guidelines

filter integrity testing fda guidelines
Adriacin HCL (FDA)

Adriacin HCL (FDA)
Thiophosphoramide (FDA)

Thiophosphoramide (FDA)
Aciclovir (FDA)

Aciclovir (FDA)
Bleomycin sulfate (FDA)

Bleomycin sulfate (FDA)
Fluorouracil deoxyriboside( FDA)

Fluorouracil deoxyriboside( FDA)
Semaglutide(FDA)

Semaglutide(FDA)
Vecuronium (FDA)

Vecuronium (FDA)

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service